User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Rituximab and chemotherapy in diffuse large B-cell lymphoma.

Primary tabs

Sonet, Anne [UCL] Bosly, André [UCL]

Rituximab is an anti-CD20 chimeric monoclonal antibody with activity in nearly all subtypes of B-cell lymphomas. Association of rituximab with chemotherapy (mostly the cyclophosphamide, doxorubicin, vincristine and prednisolone [CHOP] regimen) in diffuse large B-cell lymphoma (DLBCL) represents an extraordinary revolution in the prognosis of DLBCL, and is the new standard of therapy in elderly and young, low-risk patients. Despite the lack of randomized, clinical trials in younger patients with high risk, rituximab is also a standard of care in these patients in clinical practice, at least in North America. The practice is based on observational trials (e.g., the British Columbia Registry) and the missing logic in classifying patients as 'younger' or 'older': 60 years old or 65 years old. In Europe, trials are ongoing to establish the best treatment for young, high-risk patients. Association of rituximab and chemotherapy deeply modifies prognostic factors defined before the rituximab era.

Document type Article de périodique (Journal article) – Journal Article, Review
Publication date 2009
Journal information "Expert Review of Anticancer Therapy" - Vol. 9, no. 6, p. 719-726 (2009)
Peer reviewed yes
Publisher Expert Reviews Ltd. ((United Kingdom) London)
issn 1473-7140
e-issn 1744-8328
Publication status Publié
Affiliations UCL - MED - Sciences médicales
UCL - (MGD) Service d'hématologie
MESH Subject Age Factors ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage - therapeutic use ; Clinical Trials as Topic ; Cyclophosphamide - administration & dosage ; Doxorubicin - administration & dosage ; Humans ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Middle Aged ; Prednisolone - administration & dosage ; Prognosis ; Risk Factors ; Vincristine - administration & dosage
Links
  1. Jazirehi Ali R, Bonavida Benjamin, Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention, 10.1038/sj.onc.1208349
  2. Selenko N, Majdic O, Draxler S, Berer A, Jäger U, Knapp W, Stöckl J, CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells, 10.1038/sj.leu.2402226
  3. Bello C., Sotomayor E. M., Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond, 10.1182/asheducation-2007.1.233
  4. Maloney, Blood, 90, 2188 (1997)
  5. McLaughlin, J. Clin. Oncol., 16, 2825 (1998)
  6. Colombat P., Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, 10.1182/blood.v97.1.101
  7. Ghielmini M., Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, 10.1182/blood-2003-10-3411
  8. Hainsworth John D., Litchy Sharlene, Shaffer Don W., Lackey Van L., Grimaldi Manuel, Greco F. Anthony, Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network, 10.1200/jco.2005.12.191
  9. Czuczman, J. Clin. Oncol., 17, 268 (1999)
  10. Czuczman Myron S., Weaver Robin, Alkuzweny Baha, Berlfein Judy, Grillo-López Antonio J., Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up, 10.1200/jco.2004.04.020
  11. Marcus R., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, 10.1182/blood-2004-08-3175
  12. Hiddemann W., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, 10.1182/blood-2005-01-0016
  13. Herold Michael, Haas Antje, Srock Stefanie, Neser Sabine, Al-Ali Kathrin Haifa, Neubauer Andreas, Dölken Gottfried, Naumann Ralph, Knauf Wolfgang, Freund Mathias, Rohrberg Robert, Höffken Klaus, Franke Astrid, Ittel Thomas, Kettner Erika, Haak Ursula, Mey Ulrich, Klinkenstein Christian, Aβmann Michael, von Grünhagen Ullrich, Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, 10.1200/jco.2006.06.4618
  14. Salles, Blood, 110, 243a (2007)
  15. Turturro Francesco, Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival, 10.1586/14737140.7.7.959
  16. Coiffier, Blood, 92, 1927 (1998)
  17. Vose J. M., Link B. K., Grossbard M. L., Czuczman M., Grillo-Lopez A., Fisher R. I., Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, 10.1080/10428190500217312
  18. Fisher Richard I., Gaynor Ellen R., Dahlberg Steve, Oken Martin M., Grogan Thomas M., Mize Evonne M., Glick John H., Coltman Charles A., Miller Thomas P., Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma, 10.1056/nejm199304083281404
  19. Coiffier Bertrand, Lepage Eric, Brière Josette, Herbrecht Raoul, Tilly Hervé, Bouabdallah Reda, Morel Pierre, Van Den Neste Eric, Salles Gilles, Gaulard Philippe, Reyes Felix, Lederlin Pierre, Gisselbrecht Christian, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, 10.1056/nejmoa011795
  20. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, 10.1200/jco.2005.09.131
  21. Coiffier, J. Clin. Oncol., 25, 443S (2007)
  22. Pfreundschuh M., Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, 10.1182/blood-2003-06-2095
  23. Pfreundschuh Michael, Schubert Joerg, Ziepert Marita, Schmits Rudolf, Mohren Martin, Lengfelder Eva, Reiser Marcel, Nickenig Christina, Clemens Michael, Peter Norma, Bokemeyer Carsten, Eimermacher Hartmut, Ho Anthony, Hoffmann Martin, Mertelsmann Roland, Trümper Lorenz, Balleisen Leopold, Liersch Ruediger, Metzner Bernd, Hartmann Frank, Glass Bertram, Poeschel Viola, Schmitz Norbert, Ruebe Christian, Feller Alfred C, Loeffler Markus, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), 10.1016/s1470-2045(08)70002-0
  24. Habermann Thomas M., Weller Edie A., Morrison Vicki A., Gascoyne Randy D., Cassileth Peter A., Cohn Jeffrey B., Dakhil Shaker R., Woda Bruce, Fisher Richard I., Peterson Bruce A., Horning Sandra J., Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma, 10.1200/jco.2005.05.1003
  25. Morrison, Blood (ASH Annual Meeting Abstracts), 110, 8011 (2007)
  26. Sonneveld, Blood (ASH Annual Meeting Abstracts), 10, 210 (2006)
  27. Pfreundschuh Michael, Trümper Lorenz, Österborg Anders, Pettengell Ruth, Trneny Marek, Imrie Kevin, Ma David, Gill Devinder, Walewski Jan, Zinzani Pier-Luigi, Stahel Rolf, Kvaloy Stein, Shpilberg Ofer, Jaeger Ulrich, Hansen Mads, Lehtinen Tuula, López-Guillermo Armando, Corrado Claudia, Scheliga Adriana, Milpied Noel, Mendila Myriam, Rashford Michelle, Kuhnt Evelyn, Loeffler Markus, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, 10.1016/s1470-2045(06)70664-7
  28. Sehn Laurie H., Donaldson Jane, Chhanabhai Mukesh, Fitzgerald Catherine, Gill Karamjit, Klasa Richard, MacPherson Nicol, O'Reilly Susan, Spinelli John J., Sutherland Judy, Wilson Kenneth S., Gascoyne Randy D., Connors Joseph M., Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia, 10.1200/jco.2005.09.137
  29. Trneny, Blood (ASH Annual Meeting Abstracts), 10, 2444 (2005)
  30. Wilson W. H., Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy, 10.1182/blood.v99.8.2685
  31. Wilson Wyndham H, Gutierrez Martin, O'Connor Paula, Frankel Stanley, Jaffe Elaine, Chabner Bruce A, Grossbard Michael L, The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R, 10.1053/sonc.2002.30151
  32. Glass B., Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma, 10.1182/blood-2005-04-1570
  33. Zelenetz A. D., Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma, 10.1093/annonc/mdg702
  34. Kewalramani T., Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma, 10.1182/blood-2003-11-3911
  35. Philip, Blood, 77, 1587 (1991)
  36. Mey Ulrich J. M., Olivieri Attilio, Orlopp Katjana S., Rabe Christian, Strehl John W., Gorschlueter Marcus, Hensel Manfred, Flieger Dimitri, Glasmacher Axel G., Schmidt-Wolf Ingo G. H., DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis, 10.1080/10428190600926572
  37. El Gnaoui T, Dupuis J, Belhadj K, Jais J-P, Rahmouni A, Copie-Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F, Haioun C, Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy, 10.1093/annonc/mdm133
  38. Morschhauser F., Illidge T., Huglo D., Martinelli G., Paganelli G., Zinzani P. L., Rule S., Liberati A. M., Milpied N., Hess G., Stein H., Kalmus J., Marcus R., Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation, 10.1182/blood-2007-01-068056
  39. Czuczman M. S., Grillo-López A. J., Alkuzweny B., Weaver R., Larocca A., Mclaughlin P., Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab, 10.1080/10428190600709523
  40. Winter J. N., Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study, 10.1182/blood-2005-10-4222
  41. Hermine, Blood, 87, 265 (1996)
  42. Mounier N., Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL), 10.1182/blood-2002-11-3442
  43. Wilson Wyndham H., Dunleavy Kieron, Pittaluga Stefania, Hegde Upendra, Grant Nicole, Steinberg Seth M., Raffeld Mark, Gutierrez Martin, Chabner Bruce A., Staudt Louis, Jaffe Elaine S., Janik John E., Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers, 10.1200/jco.2007.13.1391
  44. Liu Y.-Y., Leboeuf C., Shi J.-Y., Li J.-M., Wang L., Shen Y., Garcia J.-F., Shen Z.-X., Chen Z., Janin A., Chen S.-J., Zhao W.-L., Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma, 10.1182/blood-2006-09-049189
  45. Rosenwald Andreas, Wright George, Chan Wing C., Connors Joseph M., Campo Elias, Fisher Richard I., Gascoyne Randy D., Muller-Hermelink H. Konrad, Smeland Erlend B., Giltnane Jena M., Hurt Elaine M., Zhao Hong, Averett Lauren, Yang Liming, Wilson Wyndham H., Jaffe Elaine S., Simon Richard, Klausner Richard D., Powell John, Duffey Patricia L., Longo Dan L., Greiner Timothy C., Weisenburger Dennis D., Sanger Warren G., Dave Bhavana J., Lynch James C., Vose Julie, Armitage James O., Montserrat Emilio, López-Guillermo Armando, Grogan Thomas M., Miller Thomas P., LeBlanc Michel, Ott German, Kvaloy Stein, Delabie Jan, Holte Harald, Krajci Peter, Stokke Trond, Staudt Louis M., The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, 10.1056/nejmoa012914
  46. Hans C. P., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, 10.1182/blood-2003-05-1545
  47. Nyman H., Adde M., Karjalainen-Lindsberg M.-L., Taskinen M., Berglund M., Amini R.-M., Blomqvist C., Enblad G., Leppa S., Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy, 10.1182/blood-2006-09-047068
  48. Sehn L. H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K. J., Shenkier T., Sutherland J., Gascoyne R. D., Connors J. M., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, 10.1182/blood-2006-08-038257
  49. Haioun C., [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome, 10.1182/blood-2005-01-0272
  50. Dupuis J., Gaulard P., Hemery F., Itti E., Gisselbrecht C., Rahmouni A., Copie-Bergman C., Briere J., Gnaoui T. E., Gaillard I., Meignan M., Haioun C., Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma, 10.3324/haematol.10895
  51. Delarue, Blood (ASH Annual Meeting Abstracts), 108, 689a (2006)
  52. Micallef Ivana N. M., Kahl Brad S., Maurer Matthew J., Dogan Ahmet, Ansell Stephen M., Colgan Joseph P., Geyer Susan, Inwards David J., White William L., Habermann Thomas M., A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma, 10.1002/cncr.22342
  53. Ganjoo Kristen N., An Caroline S., Robertson Michael J., Gordon Leo I., Sen Joy A., Weisenbach Jill, Li Shuli, Weller Edie A., Orazi Attilio, Horning Sandra J., Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis, 10.1080/10428190600563821
  54. Rice, Blood (ASH Annual Meeting Abstracts), 110, 1280 (2007)
  55. Gisselbrecht, Blood (ASH Annual Meeting Abstracts), 110, 517 (2007)
Bibliographic reference Sonet, Anne ; Bosly, André. Rituximab and chemotherapy in diffuse large B-cell lymphoma.. In: Expert Review of Anticancer Therapy, Vol. 9, no. 6, p. 719-726 (2009)
Permanent URL http://hdl.handle.net/2078.1/24928